Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience

SIMPLE SUMMARY: The advent of immune-checkpoint inhibitors (ICIs) has significantly changed the management of patients with non-small cell lung cancer (NSCLC). Although the assessment of PD-L1 expression remains the gold standard for the selection of cases for immunotherapy, previous experiments hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Monaco, Lavinia, Gemelli, Maria, Gotuzzo, Irene, Bauckneht, Matteo, Crivellaro, Cinzia, Genova, Carlo, Cortinovis, Diego, Zullo, Lodovica, Ammoni, Luca Carlofrancesco, Bernasconi, Davide Paolo, Rossi, Giovanni, Morbelli, Silvia, Guerra, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037395/
https://www.ncbi.nlm.nih.gov/pubmed/33915801
http://dx.doi.org/10.3390/cancers13071634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037395/
https://www.ncbi.nlm.nih.gov/pubmed/33915801
http://dx.doi.org/10.3390/cancers13071634

Ejemplares similares